Last reviewed · How we verify
atypical antipsychotic drug
At a glance
| Generic name | atypical antipsychotic drug |
|---|---|
| Sponsor | Osaka City University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacist-led Interventions in Psychiatric Patients (NA)
- Caplyta in Borderline Personality Disorder (PHASE2)
- Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial. (NA)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
- A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication (PHASE3)
- An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication (PHASE3)
- Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia (PHASE4)
- Non-Invasive Fundus Retinal Detection Technology for Early Diagnosis of Parkinson's Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- atypical antipsychotic drug CI brief — competitive landscape report
- atypical antipsychotic drug updates RSS · CI watch RSS
- Osaka City University portfolio CI